http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Long-term outcomes of intraoperative and perioperative albendazole treatment in hepatic hydatidosis
Kagan Karabulut,G. Selcuk Ozbalci,Tugrul Kesicioglu,Ismail Alper Tarim,Gokhan Lap,Ayfer Kamali Polat,Ilhan Karabıcak,Kenan Erzurumlu 대한외과학회 2014 Annals of Surgical Treatment and Research(ASRT) Vol.87 No.2
Purpose: The aim of this study was to evaluate long-term outcome of the intraoperative and perioperative albendazole (ALB) treatment on the recurrence and/or secondary hydatidosis. Methods: One hundred and one patients with hepatic hydatidosis were treated intraoperatively and perioperatively with ALB, in addition to surgery. Perioperative ALB treatment was given in a dose of 12?15 mg/kg/day. The ALB treatment was started 13.27 ± 14.34 days before the surgery, and it was continued for 4.39 ± 3.11 months postoperatively. A total of 1.7 mg/mL of ALB solution was used as a protoscolidal agent. The follow-up period was 134.55 ± 51.56 months. Results: Four patients died, with only one death was secondary to hydatid disease (cerebral eccinococcus). There was only one recurrence (1%) of hepatic hydatidosis. Early and late morbidity rates were 8.91% and 7.92%, respectively. Conclusion: Our results suggest that intraoperative and perioperative ALB is effective for the prevention of hepatic hydatidosis recurrence and/or secondary hydatidosis.